人類乳突病毒市場：規模、細分、份額、法規、報銷、程序、到 2033 年的預測

人類乳突病毒（HPV）被稱為世界上最常見的性傳染感染（STI）。 人類乳突病毒 (HPV) 檢測主要用於篩檢子宮頸癌和/或識別子宮頸癌風險較高的女性。 HPV有150多種類型，包括高危險HPV和低危險HPV。 在這些類型中，HPV-16 和 HPV-18 最常與子宮頸癌的發生有關。

核酸擴增（NAAT）檢測是HPV檢測的主流，具有較高的特異性和敏感性，可適應高通量檢測。 已經報導了其他幾種 HPV DNA 檢測方法，包括原位雜交測試、□聯免疫吸附測定 (EIA) 或□聯免疫吸附測定 (ELISA) 試劑盒以及下一代測序測定。 有利的政府政策、HPV 感染的高發生率以及子宮頸癌篩檢意識計劃的提高等因素預計將在預測期內推動整個 HPV 檢測市場的發展。 尖圭濕疣通常是由非致癌性 HPV 病毒株（例如 HPV-6 和 HPV-11）引起的。

HPV檢測包括人類乳突病毒（HPV）核酸擴增檢測（NAAT）和其他人類乳突病毒（HPV）檢測試劑盒。

本報告深入探討了全球人類乳突病毒市場，包括競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。Masu。

目錄

目前市面上的人類乳突病毒及競爭狀況

• 對主要產業趨勢的見解
• 2015 年至 2033 年按細分市場劃分的人類乳突病毒市場總收入及市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• 人類乳突病毒市場的SWOT分析
• 人類乳突病毒市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

Human Papilloma Virus Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Human Papilloma Virus Tests market for the year 2020 and beyond. Human papillomavirus (HPV) is known as the most common sexually transmitted infection (STI) in the world. Human Papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. There are over 150 types of HPV including both high-risk HPV and low-risk HPV. Out of these strains, types HPV-16 and HPV-18 are most commonly associated with development of cervical cancer.

The predominant devices used for HPV detection are Nucleic-acid amplification (NAAT) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. Several other HPV DNA detection methods have also been described including in situ hybridization tests, Enzyme Immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) kits, and next generation sequencing assays. Factors like favorable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness plans are expected to drive the overall HPV testing market during the forecast period. Genital warts are often caused by non-oncogenic strains of HPV, such as HPV-6 and HPV-11.

The HPV tests includes Human Papilloma Virus (HPV) Nucleic Acid Amplification Tests (NAATs) and Other Human Papilloma Virus (HPV) Test Kits.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Human Papilloma Virus Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Human Papilloma Virus Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Human Papilloma Virus market.
• Competitive dynamics insights and trends provided for Human Papilloma Virus market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Qiagen NV, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Biocare Medical LLC, Enzo Biochem Inc, Danaher Corp, Thermo Fisher Scientific Inc and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Human Papilloma Virus (HPV) Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Human Papilloma Virus (HPV) Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Human Papilloma Virus (HPV) Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Human Papilloma Virus (HPV) Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Human Papilloma Virus (HPV) Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.